<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="American Express Co. AXP second-quarter 2019 earnings of $2.07 per share surpassed the Zacks Consensus Estimate by 0.98% and were up 12.5% year over year.” data-reactid=”11″>American Express Co. AXP second-quarter 2019 earnings of $2.07 per share surpassed the Zacks Consensus Estimate by 0.98% and were up 12.5% year over year.
Total revenues of $10.8 billion beat the Zacks Consensus Estimate by 0.14% and were up 8.4% year over year. This is the eighth straight quarter in which the company posted foreign exchange adjusted revenue growth of more than 8%. This growth continues to be driven by a well balanced mix of spending, fees and loans spread across geographies and customer segments.
The company continues to witness solid trends in Card Member spending led by consumers. This spending can be attributed to an economy that is growing but at a modest pace relative to 2018.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="American Express Company Price, Consensus and EPS Surprise” data-reactid=”14″>American Express Company Price, Consensus and EPS Surprise
American Express Company price-consensus-eps-surprise-chart | American Express Company Quote
Provisions for loss totaled $861 million, up 7% year over year, which was attributable to growth in loan (up 11% year over year), receivable portfolio and an increase in higher write-offs.
Total expenses of $7.8 billion increased 9% year over year, due to growth in rewards and other customer engagement costs driven by increased Card Member spending, higher usage of card benefits and continued investments in co-brand partnerships.
During the quarter, the company added 2.9 million new proprietary cards.Nearly 70% of these new cards carry an annual fee, which reinstates the fact that Card Members are taking up cards and willing to pay for premium value.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Segment Update” data-reactid=”31″>Segment Update
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Strong Segmental Results” data-reactid=”32″>Strong Segmental Results
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="American Express’ Global Consumer Services segment reported net income of $738 million, down 4% year over year. Total revenues, net of interest expenses of $5.8 billion, were up 10% year over year, reflecting higher loans and Card Member spending as well as fee income.” data-reactid=”33″>American Express’ Global Consumer Services segment reported net income of $738 million, down 4% year over year. Total revenues, net of interest expenses of $5.8 billion, were up 10% year over year, reflecting higher loans and Card Member spending as well as fee income.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Global Commercial Services’ net income of $644 million was up 14% year over year. Total revenues, net of interest expenses, increased 7% year over year to $3.4 billion, primarily reflecting higher Card Member spending.” data-reactid=”34″>Global Commercial Services’ net income of $644 million was up 14% year over year. Total revenues, net of interest expenses, increased 7% year over year to $3.4 billion, primarily reflecting higher Card Member spending.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Global Merchant and Network Services’ net income rose 16% year over year to $632 million in the reported quarter. Total revenues and net of interest expenses were up 5% year over year to $1.7 billion.” data-reactid=”35″>Global Merchant and Network Services’ net income rose 16% year over year to $632 million in the reported quarter. Total revenues and net of interest expenses were up 5% year over year to $1.7 billion.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Guidance Update” data-reactid=”36″>Guidance Update
American Express has reaffirmed its financial guidance for 2019. The company expects revenue growth of 8%–10% this year. In addition, its adjusted EPS guidance range for 2019 is $7.85–$8.35.
The company also expects to increase the regular quarterly dividend by 10.3% to 43 cents per share, beginning with the third quarter of 2019, subject to approval by its board of directors.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="American Express carries a Zacks Rank #3 (Hold).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.” data-reactid=”39″>American Express carries a Zacks Rank #3 (Hold).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Here are some finance stocks that you may want to consider as our model shows that these have the right combination of elements to beat on earnings in the upcoming releases.
Discover Financial Services DFS has an Earnings ESP of +0.18% and a Zacks Rank #3 (Hold).
PayPal Holdings, Inc. PYPL has an Earnings ESP of +11.19% and a Zacks Rank of 2 (Buy).
Mastercard Inc. MA has an Earnings ESP of +0.55% and a Zacks Rank of 3.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Breakout Biotech Stocks with Triple-Digit Profit Potential” data-reactid=”44″>Breakout Biotech Stocks with Triple-Digit Profit Potential
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>” data-reactid=”45″>The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PayPal Holdings, Inc. (PYPL) : Free Stock Analysis Report
Discover Financial Services (DFS) : Free Stock Analysis Report
American Express Company (AXP) : Free Stock Analysis Report
Mastercard Incorporated (MA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research” data-reactid=”46″>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PayPal Holdings, Inc. (PYPL) : Free Stock Analysis Report
Discover Financial Services (DFS) : Free Stock Analysis Report
American Express Company (AXP) : Free Stock Analysis Report
Mastercard Incorporated (MA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Add Comment